Abstract 350P
Background
Carcinoembryonic antigen (CEACAM) or CD66+ is categorized as type N2 tumour associated neutrophils (TAN), an immunoreceptor expressed on activated neutrophils. It is also known as marker for neutrophil specific granules. This marker is expressed on tumour tissue, has strong immunosuppressive and tumour promoting acttivities including angiogenesis, invasion, and metastasis through various mechanism. This study aimed to assess intratumoural CD66B+ TAN to predict clinical treatment response in patients with diffuse large B cell lymphoma (DLBCL).
Methods
This prognostic study was conducted in Palembang, South Sumatera, Indonesia in 2020. The subjects were 18 - 70 years old DLBCL patients, enrolled by consecutive sampling using medical record. The immunohistochemistry TAN CD66b+ was examined by pathologist. Chemotherapy response was assessed clinically (hematological and radiological) after minimum two cycles of RCHOP regimen. Patients with HIV, relapsed DLBCL, other malignancies, and delayed chemotherapy were excluded.
Results
Of the 21 subjects consisted of 11 men (52,4%), the most subtype (95,2%) was DLBCL non-GCB, prognostic high-risk IPI score 42,9% and intermediate-risk 57,1%. Subjects who achieved complete remission response were 9 people (42,9%). The cut-off value for the CD66b+ TAN density was 21,7 cells/mm2. A total of 76,9% of subjects with high density CD66b+ TAN did not achieve any remission (p=0.029), with sensitivity 83,3% and specificity 66,7%.
Conclusions
We found that density levels of intratumoural CD66b+ TAN in tumour tissue has significant correlation with non-responder (poor prognosis) DLBCL patients.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
101P - The coexistence of TP53 gain-of-function mutation and hypermethylation as a poor prognostic factor in BRAF wild-type metastatic colorectal cancer
Presenter: Kota Ouchi
Session: Poster Display
Resources:
Abstract
102P - Enhancing colorectal cancer prevention in high-risk populations through faecal immunochemical test surveillance
Presenter: Li Xie
Session: Poster Display
Resources:
Abstract
103P - Anlotinib plus chemotherapy as first-line therapy for gastrointestinal tumor patients with unresectable liver metastasis: Updated results from a multi-cohort, multi-center phase II trial ALTER-G-001-cohort A
Presenter: Junwei Wu
Session: Poster Display
Resources:
Abstract
104P - The value of functional MR-imaging signature model for early prediction of chemotherapy response and its guidance for regimen adjustment to improve efficacy
Presenter: Wenhua Li
Session: Poster Display
Resources:
Abstract
105P - A single-arm, phase II, multicenter study of iparomlimab (QL1604) in patients (pts) with unresectable/metastatic deficient mismatch repair (dMMR)/microsatellite instability high (MSI-H) solid tumors
Presenter: Weijian Guo
Session: Poster Display
Resources:
Abstract
106P - Efficacy and safety of IBI351 (GFH925) monotherapy in metastatic colorectal cancer harboring KRASG12C mutation: Updated results from a pooled analysis of two phase I studies
Presenter: Ying Yuan
Session: Poster Display
Resources:
Abstract
107P - Tumor-stromal ratio in a new age fibroblast activated protein PET imaging as a biomarker for prediction of response to neoadjuvant chemoradiotherapy in carcinoma rectum
Presenter: swetha Suresh
Session: Poster Display
Resources:
Abstract
108P - Detection of HER2 overexpression in colorectal cancer: Comparison of a HANDLE classic NGS panel with standard IHC/FISH
Presenter: Lijuan Luan
Session: Poster Display
Resources:
Abstract
109P - Early onset metastatic colorectal cancer: Clinical-prognostic characteristics and correlation to molecular status
Presenter: Andrea Pretta
Session: Poster Display
Resources:
Abstract
110P - The correlation between multi-dimensional characteristics of circulating tumor cells (CTC) and treatment response in patients with initially unresectable metastatic colorectal cancer
Presenter: Yu Liu
Session: Poster Display
Resources:
Abstract